Cylene Pharmaceuticals, Inc.
5820 Nancy Ridge Drive, Suite 200
San Diego
California
92121
United States
Tel: 858-875-5100
Fax: 858-875-5101
Website: http://www.cylenepharma.com/
Email: info@cylenepharma.com
25 articles about Cylene Pharmaceuticals, Inc.
-
Cylene Pharmaceuticals, Inc. and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
3/6/2013
-
New Drug Stunts Tumor Growth, Cylene Pharmaceuticals, Inc. Reveals
7/18/2012
-
Cylene Pharmaceuticals, Inc. Release: Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
7/10/2012
-
Cylene Pharmaceuticals, Inc. Builds on Success, Presents Second CK2 Inhibitor at American Association for Cancer Research Meeting
4/4/2012
-
Cylene Pharmaceuticals, Inc. Builds on Success, Presents Second CK2 Inhibitor at American Association for Cancer Research Meeting
4/3/2012
-
Cylene Pharmaceuticals, Inc. First-in-Class Agents Show Promise in High Risk Blood Cancers at American Society of Hematology
12/13/2011
-
Cylene Pharmaceuticals, Inc. Advances Breakthrough p53 Activator Toward the Clinic
10/13/2011
-
Cylene Pharmaceuticals, Inc. Presents Encouraging Clinical Data for Oral CK2 Inhibitor at American Society of Clinical Oncology
6/6/2011
-
Cylene Pharmaceuticals, Inc. Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hypertension Meeting
12/6/2010
-
Cylene Pharmaceuticals, Inc. to Present Advances with Industry's Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
11/16/2010
-
Horizon Discovery Ltd. and Cylene Pharmaceuticals, Inc. Collaborate in Rational Selection of Patients for Clinical Trial
10/19/2010
-
Cylene Pharmaceuticals, Inc. Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying $12 Million Financing
9/24/2010
-
Cylene Pharmaceuticals, Inc.e to Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, at International CK2 Conference
9/8/2010
-
Cylene Pharmaceuticals, Inc. to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at Biotechnology Industry Organization (BIO) Conference
5/19/2009
-
Cylene Pharmaceuticals, Inc. to Present Advances in its Oral Inhibitor of CK2 at American Association for Cancer Research Annual Meeting
4/17/2009
-
Cylene Pharmaceuticals, Inc. to Present Advances in its Oral Inhibitor of CK2 at American Association for Cancer Research Annual Meeting
4/17/2009
-
Cylene Pharmaceuticals, Inc. Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
1/5/2009
-
Cylene Pharmaceuticals, Inc. Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
12/15/2008
-
Cylene Pharmaceuticals, Inc. Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
1/28/2008
-
Cylene Pharmaceuticals, Inc. Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations
7/10/2007